Korsana Biosciences, Inc. Common Stock
KRSA
69 hedge funds and large institutions have $62.5M invested in Korsana Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 8 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 15
1.37% more ownership
Funds ownership: 64.39% → 65.76% (+1.4%)
1% less funds holding
Funds holding: 70 → 69 (-1)
7% less capital invested
Capital invested by funds: $66.9M → $62.5M (-$4.42M)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
41% less call options, than puts
Call options by funds: $59K | Put options by funds: $100K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$161K |
| 2 |
Renaissance Technologies
New York
|
+$116K |
| 3 |
Two Sigma Advisers
New York
|
+$60.8K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$53.3K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$50.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$201K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$191K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$157K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$106K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$78K |
KRSA Hedge Fund Activity: Q1 2021 in Review
69 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q1 2021, worth a combined $62.5M — down 6.6% from $66.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of KRSA and 7 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 26 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $161K. The largest seller was Morgan Stanley, cutting an estimated $201K.
- 69 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q1 2021, down from 70 in Q4 2020.
- Funds reported $62.5M of Korsana Biosciences, Inc. Common Stock stock for Q1 2021, down 6.6% quarter-over-quarter.
- 7 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of -1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q1 2021 was Ikarian Capital, an estimated $161K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q1 2021 was Morgan Stanley, an estimated $201K sold.
Based on aggregated 13F filings for Q1 2021.